Dr. Bing Xia is an accomplished chemist with over 15 years of experience in the field of DNA Encoded Library (DEL) R&D, having earned his Ph.D. from Boston University under the mentorship of the renowned photochemist, Prof. Guilford Jones, and in collaboration with Prof. John Porco. During his time at GSK (Boston, USA), he distinguished himself as a GSK Associate Fellow and led numerous projects across various therapeutic areas including oncology, CNS, immunology, and infectious diseases/HIV. Dr. Xia's exceptional contributions to science have been recognized with multiple awards, including 3 Exceptional Science Awards, 2 Cool Chemistry Finalists, 5 Silver Awards, and 10 Bronze Awards. He was also a finalist in the GSK $5K Electroceutical Ideation Challenge and the $1 million InnoCentive. As a key organizer of prominent industry conferences, including the GSK 2019 Global Chemistry Conference and the 8th International Symposium on DNA Encoded Chemical Libraries, and as an expert reviewer for over 100 submissions to high-impact journals. His research has resulted in the publication of more than 20 articles, book chapters, and patents in esteemed journals such as Nature Communications, JACS, and the Journal of Medicinal Chemistry.

Dr. Timothy Dwight has over 12 years of experience in drug discovery. He earned a masters degree at the University of Rhode Island under Brenton Deboef, a PhD degree at UCLA under the guidance of professor Michael Jung and was a post-doctoral fellow at Northwestern University in the lab of professor Richard Silverman. Tim began his discovery career at Ariad Pharmaceuticals where he was a scientific contributor in the development of Brigatinib, an ALK-fusion and EGFR inhibitor. Later he joined Vertex pharmaceuticals and is featured on several patents related to the development of new cystic-fibrosis correctors. In 2018 he joined Silicon Therapeutics, which become Roivant Sciences, where he led chemistry efforts for the development of SNX-281, a clinical small molecule STING agonist. There he also led both chemistry and/or projects for oncology and immuno-oncology related programs. Before joining Viva, he was the founding employee and head of chemistry at Differentiated Therapeutics, where he led discovery efforts for the development of DXTX-1464, a dual CDK2 and Cyclin E degrader for the treatment of cyclin E aberrant cancers.

Victoria Ouroutzoglou is a Business Development Associate Director at Viva Biotech where she works with biotech and pharmaceutical partners to support integrated drug discovery programs spanning screening, medicinal chemistry, structural biology, AI-driven discovery platforms and more. Based in Cambridge, Massachusetts, Victoria brings a strong background in life sciences and translational research, with experience connecting scientific innovation to strategic collaboration opportunities. She is passionate about advancing early stage drug discovery through cross functional partnerships and emerging technologies. In her free time she enjoys a good coffee and engaging with local non profit organizations that support early scientific education in underrepresented demographics.